Phase 1 Brain Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 75 years old at the time of signing consent
• People who have been diagnosed with glioblastoma (a type of aggressive brain tumour, WHO grade 4) or a related high-grade brain tumour (WHO grade 3 or 4) that has come back or continued to grow after standard treatment
• People who are scheduled for, or have already had, a surgical procedure to remove or sample their tumour — or who have stored tumour tissue available — so that specific tumour proteins can be tested and a small tube can be placed in or near the tumour
• People whose tumour shows a high enough level of at least two of these specific proteins: IL13Rα2, EGFR (including a variant called EGFRvIII), or B7-H3 (confirm with trial site for exact thresholds)
• People with a functional ability score of 60 or above on the Karnofsky Performance Scale, meaning someone still able to care for most of their own needs (confirm with trial site)
• People whose blood tests show the heart, kidneys, and liver are working at levels that meet the trial's requirements
• People who are able to have a brain MRI scan with contrast dye, or where an alternative type of scan has been approved by the trial site
• Women who could become pregnant must have a negative pregnancy test, and all participants must agree to use effective contraception during the study and for a set period afterwards
• People who are able to understand the study information and are willing to sign a consent form

Who may not be able to join:

• People who have an active infection that is not under control, such as a bacterial, viral, or fungal infection
• People with HIV who have a detectable level of the virus in their blood, or people with active hepatitis B or hepatitis C with a detectable viral load (confirm with trial site for any exceptions)
• People who have a significant autoimmune disease — where the immune system attacks the body — that has required medication to suppress the immune system in the past 6 months
• People who have needed high doses of steroid medication (such as more than 4 mg per day of dexamethasone or equivalent) in the 7 days before the scheduled treatment (low-dose steroids taken to replace what the body naturally produces may be permitted — confirm with trial site)
• People who have received a previous gene-modified cell therapy (such as CAR-T or CAR-NK therapy) within the past 6 months, or who have previously had treatment targeting the same tumour proteins this trial focuses on, in a way that could affect safety assessments
• People whose tumour has spread only to the lining around the brain and spinal cord with no other tumour site, or whose anatomy makes it unsafe to place the required small tube near the tumour (confirm with trial site for any exceptions)
• People who have seizures that are not controlled even with the best available medication
• People with serious heart or blood vessel problems — such as a recent heart attack or an irregular heartbeat that is not under control — that would make the treatment procedures too risky
• People who are pregnant or breastfeeding
• People who have any other condition that the trial doctor believes would make participation unsafe or would make it difficult to follow the trial's requirements

Important: Always verify eligibility with the trial site directly before applying.